Chronic Heart Failure | Norton Healthcare

Indication: Chronic Heart Failure

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF)

With preserved ejection fraction

Drug Study

Principal Investigator: Janet Smith, M.D.
Norton Heart & Vascular Institute

Sponsor: Boehringer Ingelheim

Learn more at ClinicalTrials.gov

Email for more information: CVResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.